

Pedal Diabetes: Available Products and Services/ New Technologies

Here are tools for prevention, diagnosis, and treatment.

Clinical Data Shows SkinIntegra Working Faster than Urea-40% Cream on Pedal Fissures

SkinIntegra, an emerging therapeutic skin care company, announces that a randomized, double blind 4-week clinical trial conducted by the Western School College of Podiatric Medicine, aiming to assess the comparative efficacy of Urea-40 and SkinIntegra for addressing pedal fissures, has shown that its Rapid Crack Repair Cream delivers faster improvement in

dryness and cracking than urea-40 with less irritation after extended application. "This new clinical data supports that our product may offer a more efficacious and tolerable alternative to urea-40 for managing pedal fissures," said Erika Tazberik, SkinIntegra's Chief Technology Officer and Co-Founder.

What sets Rapid Crack Repair Cream apart from other products is its fast-acting, gentle formula. SkinIntegra developed and patented an innovative formula featuring 25%



urea and lactic acid, specifically crafted to heal skin fissures while reducing potential side effects by avoiding salicylic acid. SkinIntegra uses barrier renewing ingredients such as lipids and ceramides, which help the skin retain moisture and stay hydrated without breaking down the surrounding tissue. It is also free of fragrances and dyes.

Originally developed for people with diabetes suffering from infection-prone cracks to their feet, Rapid Crack Repair Cream has proven to be efficacious in providing fast

relief to many hard-to-treat skin cracking conditions. Its patented skin barrier repair composition precisely mimics the content of the skin barrier and works in harmony with the skin. Its lightweight texture allows for quick absorption, making it suitable for use on various parts of the body, including hands, feet, elbows, and knees. For more information, visit www.skinintegra.com, click here, or call (442) 226-2262.

Continued on page 98

MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix

iMedx Group, Inc. announced the commercial launch of HELIOGEN" Fibrillar Collagen Matrix, a particulate xenograft product aimed at addressing complex wounds. HELIOGEN is a shelf-stable offering that contains native components of an extracellular matrix including, type I and type III collagen.

"We are pleased to introduce our first xenograft option and 510(k) cleared product to complement our leading placental-based solutions in the surgical market," stat-

HELIOGEN™
FIBRILLAR COLLAGEN MATRIX

ed Joseph H. Capper, MIMEDX Chief Executive Officer. Eric Smith, MIMEDX Senior Vice President, Mar-

keting & International, added, "HELIOGEN is an exciting addition to our portfolio and provides another tool to help our customers manage complex wounds. With a solid foundation of initial case studies and

real-world evidence, we are excited for customers in various surgical settings to build on this evidence and realize improved outcomes for their patients."

About HELIOGEN

HELIOGEN is a 510(k) cleared, bovine-derived col-

lagen matrix product indicated for the management of moderately to heavily exudating wounds and to control minor bleeding. The collagen in this product serves as a dressing that

allows for cell adhesion and migration into the wound site and supports wound healing. It is provided in particulate form allowing it to be molded or packed to conform to various wound types such as pressure ulcers, venous stasis ulcers, diabetic ulcers, acute wounds. *To learn more about HELIOGEN*, *visit www.mimedx.com/heliogen/ or click here.*



Heal More DFU's Faster Using the Defender DFU Patient Platform

Defender's mission is to address the root causes of DFUs and improve patient outcomes. The firm has developed the Defender DFU Patient Platform to provide a continuum of care that shifts away from traditional reactive treatments. Focusing on prevention, early intervention, and long-term management, it combines remote patient monitoring, compliance measurement, AI-driven analytics, and wearable smart devices.

Defender's flagship product, the Smart Boot", is easy to use, stylish, and reduces pressure on the foot to facilitate faster wound healing. It uses advanced



Once the wound has healed, Defender has now introduced the Cloud 9 to help with the transition. This product is a comfortable and protective clog that takes the same offloading principles from the Smart Boot. It applies them in a less restrictive form to allow patients to continue protecting their feet without compromising comfort.

These innovative products are connected through Defender's disease management platform; the key components are the Sensoria Core* and the Smart Watch app. This platform enables caregivers to monitor patient adherence to treatment protocols, using the cloud-based dashboard. The dashboard reports activity levels, steps taken, device usage, and compliance to ensure patients wear their Smart Boot* or other devices as prescribed.

Visit www.footDefender.com or click here for more information.



AOTI Offers Multi-Modality Topical Wound Oxygen (TWO2) Therapy to Treat Non-Healing DFUs

AOTI's mission is to help all people with chronic conditions get back to living life to the fullest. Diabetic, non-healing wounds are a significant burden to the healthcare system, and often require the implementation of advanced interventions or modalities to address both local and systemic factors interfering with the healing progression.

The critical element that is always missing in non-healing wounds is adequate levels of oxygen in the wounded tissue. While acute hypoxia is a necessary step after an injury for cellular signaling, chronic hypoxia results in a prolonged inflammatory phase that stalls the natural healing process.

AOTI offers the only multi-modality topical wound oxygen (TWO2) therapy that by using a combination of non-contact cyclical compression, higher-pressure oxygen and humidification, applied directly to the wound, supports all phases of the wound healing continuum, resulting in highly durable healing. TWO2 has been proven in the most robust randomized controlled trials and real-world evidence studies to significantly reduce wound reoccurrence, hospitalizations and amputations over 12 months.

AOTI's landmark TWO2 randomized controlled trial was recognized in 2023 as one of the "TOP 4 STUDIES OF THE LAST 4 YEARS" at the 9th International Symposium on the Diabetic Foot. Highest level evidence-based medicine, combined with level 1/A clinical practice guidelines treatment recommendations from the American Diabetes Association and Wound Healing Society, supports

the best clinical outcomes for your patients, so life can get back to normal. AOTI is your trusted partner providing engaged outcomes that you can rely on. TWO2 therapy can be administered in any clinical setting and is commonly self-administered by the patient at home, improving access to care and treatment compliance, thereby helping to advance health equity, im-

proved outcomes and reduced costs.

Visit https://aotinc.net or click here for more information.

Ped-Lite Introduces App to Help Streamline your Orthotics Business

Since 2006, Ped-Lite has gone above and beyond to offer a full line of high-quality diabetic shoes, inserts, and fabrication materials at a price you can afford. Now, the firm is offering the tech to make your orthotics business



better. Eliminate bio-foam and shipping costs with the Ped-Lite Orthotics App. Download the free scanning software on your smart device for fast and accurate imaging. This is scanning and ordering at its easiest. Ped-Lite's first-class customer service and orthotic lab can help you streamline your ordering process, saving time and money for and your patients. Custom orthotics turnaround time is 5-7 business days. Customer service and satisfaction are Ped-Lite's top priority. If you are not yet one of their many customers, feel free to contact them at https://pedlite.com, click here, or call 219-756-0901 and ask for a sample of their shoes or a tutorial of their app.

Continued on page 99



Arche Healthcare Tackles Diabetic Foot Ulcers with Arche LEAP Vitals Utilization and Outcomes Demonstration Study on Skin Integrity

Arche Healthcare, a leader in proactive diabetic foot care solutions, has announced the launch of Arche LEAP (Lower Extremity Amputation Prevention) Vitals⁺ Utilization and Outcomes Demonstration Study on Skin Integrity. With a critical challenge in diabetic care, the early detection of skin issues that lead to foot ulcers and amputations is paramount. Visual assessments alone often miss key indicators of inflammation, a precursor to

skin ulceration. Arche Healthcare has developed the LEAP Vitals⁺ kit, featuring advanced tools that provide a more comprehensive understanding of skin integrity and allow for proactive—not reactive—interventions. The study addresses the critical issue of diabetic foot wounds caused by undetected skin dryness (xerosis) and "hot spots" (skin temperature) to improve the understanding of risk factors and prevent diabetes-related wounds.

Robert Frykberg, DPM, Chief Scientific Officer of Arche Healthcare, said, "The problem is, early



warning signs of diabetes often go unnoticed, leading to costly and devastating outcomes. LEAP Vitals⁺ can help prevent these wounds and help podiatrists provide proactive wound prevention. This study has the potential to improve measurable patient outcomes and practice revenue, giving podiatrists a reason to be optimistic about the future of diabetic foot care."

About Arche Healthcare

Arche Healthcare is a leader

in innovative diabetes-related skin and wound care solutions. It is dedicated to promoting purpose-driven skin healthcare solutions that prevent lower extremity amputations and improve overall skin health. Arche is at the forefront of a movement to significantly and lastingly improve the lives of individuals affected by diabetes. This study seeks to revolutionize clinical skin healthcare protocols, reduce diabetes-related foot wounds and amputations and create thriving podiatric practices.

For more information or to join the study, visit www. archehealthcare.com/study-application or click here.

Biomedix Introduces New Advanced PAD Diagnostic Solution to Podiatric Community

Biomedix is proud to announce its continued leadership in the podiatry community with cutting-edge solutions and services for peripheral artery disease (PAD) diagnostics. Recently achieving HITRUST certification, Biomedix underscores its commitment to the highest standards of data security and patient privacy.

Their latest innovation, the PADnet Xpress algorithm, demonstrates remarkable accuracy with a 96% sensitivity and 87% specificity, based on an extensive dataset of 3,945 reference records. This breakthrough ensures that health-care providers can confidently diagnose PAD with unparalleled precision.

Biomedix offers a comprehensively wide range of diagnostic solutions. The PADnet Xpress can assess for PAD with a 2-minute test, providing rapid and reli-

able results. Additionally, their 5th Generation PADnet, featuring the popular PADman interface, enables comprehensive assessments including segmental PVRs, TBIs, and venous refill studies.

"Achieving HITRUST certification is a testament to our dedication to safeguarding patient information while delivering top-tier diagnostic solutions," said Chris Trygstad, Vice President, Product at Biomedix. "Our PADnet Xpress technology sets a new standard in PAD diagnostics, ensuring accurate and timely assessments."

"We are committed to advancing podiatric care through innovative technology and exceptional service," added John Romans, CEO. "Our diverse range of diagnostic tools empowers healthcare providers to cost-effectively deliver the best possible care to their patients."

For more information, visit Biomedix. com or click here. Contact: Chris Trygstad, VP Product, ctrygstad@biomedix.com, 888-889-8997.

APWH Launches Innovative Wound Management Certification Course Amid Growing Demand

The Academy of Physicians in Wound Healing (APWH), a leading global professional association dedicated to enhancing patient outcomes in complex chronic wound care, proudly announces the launch of its new Prescribers Advanced Wound Management Certification Course.

As wound care continues to evolve without formal specialty recognition by the American Board of Medical Specialties (ABMS), the Academy remains committed to pioneering advancements in medical training. "Our mission is to elevate our educational offerings to the stature of a recognized medical specialty, ensuring our members deliver the highest standard of patient care," remarked Steven Kravitz, DPM, President

Continued on page 100

THE DIABETIC FOOT



of APWH. "This new course is meticulously designed with up-to-date content, incorporating research and practices from the past five years to keep pace with current medical standards," he added.

The 20-lesson course covers essential topics such as maintaining skin integrity, managing chronic, arterial, and venous ulcers, diabetic foot wounds, atypical wounds, skin substitutes, CTPs/CAMPS, and more. Upon completing the course, eligible candidates may take the appropriate

certification exam through the Council of Medical Education and Testing (CMET), which provides credentials to a broad spectrum of healthcare professionals, including physicians, nurse practitioners, physician assistants, nurses, and physical therapists.

For more information, please contact the Academy of Physicians in Wound Healing or click here.

Media Contact: Fredrick Berg, CEO fberg@apwh.org

About APWH:

The Academy of Physicians in Wound Healing (APWH) is a premier global professional association dedicated to enhancing the lives of patients grappling with complex chronic wounds. With an unwavering commitment to excellence, APWH endeavors to redefine the standards of wound care through groundbreaking education, advocacy, and research initiatives.

Neurogenx Offers an Integrated Approach: Ensuring Footwear Access and Neuropathy Treatment Results

The Neurogenx (NGX) HealthStrides Outreach Initiative and Professional Affiliate Program creates awareness, educates and offers continuity of care for patients; providing easy access to a wide range of properly fitted therapeutic footwear with comprehensive services and support through NGX as an accredited DMEPOS. At no expense or risk, NGX handles all paperwork and billing of Medi-

care and other insurances and then pays the Professional Affiliate.

Properly fitted therapeutic footwear is a crucial first line of defense, preventing wounds and falls that can be life-threat-

ening for diabetic patients, who often suffer from poor circulation, peripheral neuropathy, and other complications.

In the case of peripheral neuropathy, there are many causes beyond the insult of diabetes, including radiculopathy, chemo-induced nerve damage, underlying autoimmune conditions, and other contributing factors like statins and alcohol. The majority of cases are defined as idiopathic.

Now no matter the underlying cause, NGX offers a proven and patented, FDA-cleared neuropathy treatment solution with NervePro 2.0 technology producing consistent results validated through gold-standard ENFD testing. Clinical confidence through objective validation, combined with a prov-

en medical business solution, encourages PCP engagements and often leads to low-threshold referral pathways being established and nurtured for sustainable clinical and business success.

The bottom line is that, due to a lack of viable treatment options, neuropathy patients are a very at-risk, and underserved population. The complexity of the condition and the lack of knowledge requires



NEUR GENX°
HEALTHSTRIDES
PROFESSIONAL AFFILIATE PROGRAM



NEUR GENX®
NERVEPRO 2.0
ADVANCED NERVE TECHNOLOGY



NEUR GENX*
SOLUTIONS PROGRAM
TURN-KEY MEDICAL BUSINESS SOLUTION

a multifaceted approach to care. The same is true for diabetic patients and the very low utilization of therapeutic footwear, despite its proven ability to help prevent life-threatening wounds and falls.

NGX has fostered an interesting and integrated approach by streamlining and scaling therapeutic footwear programs. These programs serve as a first line of defense while effectively treating the specific underlying cause with proven, validated technology. This reduces the risk of further health complications and increases the odds for optimal health outcomes for patients.

To find out more about NGX integrated solutions, contact them at $\$

1-800-335-7624, info@neurogenx.com, visit www. neurogenx.com, or click here.